About
Small molecule for research and various disorders
Areas of Focus
Categories
Small Molecule PharmaceuticalSoutheastern U.S.
Team (7)
Howard S
Chairman of the Board, Rafael Holdings, Inc.
Cyclo Therapeutics
board_chair
Jeffrey L
Director, Chief Operating Officer and Chief Quality Officer, Cyclo Therapeutics
Cyclo Therapeutics
executive
John Goldberg
Cyclo Therapeutics
team_member
Karen Mullen
Interim Chief Medical Officer, Cyclo Therapeutics
Cyclo Therapeutics
executive
Lori McKenna
Global Head of Patient Advocacy, Cyclo Therapeutics
Cyclo Therapeutics
team_member
Michael Lisjak
Chief Regulatory Officer, Senior Vice President for Business Development, Cyclo Therapeutics
Cyclo Therapeutics
executive
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
7
As Collaborator
0
Total Enrollment
421
By Phase
PHASE2: 1PHASE3: 1PHASE1: 2PHASE1/PHASE2: 1
By Status
UNKNOWN: 2COMPLETED: 2NOT_YET_RECRUITING: 1ACTIVE_NOT_RECRUITING: 1NO_LONGER_AVAILABLE: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06990971Lead Sponsor
Harnessing the Disease Signatures From Endometrium and Menstrual Blood to Identify Avenues for the Treatment of Chronic Conditions Such as Endometriosis and Related Pathologies: This is an Observational Study Aimed at Shedding Light on Women's Health
N/ANot yet recruiting
200 participants
Started: Jun 1, 2025 · Completed: May 31, 2029
NCT05607615Lead Sponsor
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
PHASE2Unknown
90 participants
Started: Sep 23, 2022 · Completed: Mar 31, 2024
NCT04860960Lead Sponsor
Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1
PHASE3Active, not recruiting
94 participants
Started: Jul 20, 2021 · Completed: Jun 30, 2026
NCT03893071Lead Sponsor
Open-Label Study of Long-Term Safety and Efficacy of Intravenous Trappsol Cyclo (HPβCD) in Niemann-Pick Disease Type C
PHASE1Unknown
12 participants
Started: May 23, 2019 · Completed: Mar 31, 2022
NCT02939547Lead Sponsor
Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)
PHASE1Completed
13 participants
Started: Oct 11, 2017 · Completed: Feb 10, 2020
Locations (1)
Headquarters
Gainesville, FL, United States
Map
Loading map...